Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 121Lymphoma, Mantle-Cell 68Lymphoma, Large B-Cell, Diffuse 40Lymphoma, Non-Hodgkin 31Lymphoma, Follicular 30Waldenstrom Macroglobulinemia 29Lymphoma 29Recurrence 23Lymphoma, B-Cell 22Lymphoma, B-Cell, Marginal Zone 19Neoplasms 16Leukemia 14Leukemia, B-Cell 10Multiple Myeloma 9Bronchiolitis Obliterans Syndrome 9Leukemia, Lymphoid 8Burkitt Lymphoma 8Hematologic Neoplasms 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hodgkin Disease 5Leukemia, Prolymphocytic 4Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Hairy Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Chromosome 17 deletion 3

Interventions

Irinotecan 4Oxaliplatin 3Bevacizumab 3trimebutine 3-thiocarbamoylbenzenesulfonate 2pembrolizumab 2Leucovorin 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Cetuximab 2Capecitabine 2Aspirin 2Ascorbic Acid 2repotrectinib 1pralsetinib 1napabucasin 1ibrutinib 1guadecitabine 1encorafenib 1alectinib 1XELOX 1Sutures 1Surgical Instruments 1Polyethylene Glycols 1Optical Imaging 1Ocoxin 1Levoleucovorin 1KRN-330 1Diagnosis 1Control Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Diseases × ibrutinib × Clear all
NCT03332498 2022-06-03

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
40 enrolled 12 charts
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡